Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab
Company Targets COVID-19, CAR-T, GvHD Markets
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.
You may also be interested in...
Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.